GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
GeneDx (Nasdaq: WGS) will report its financial results for Q4 and full year 2022 on March 14, 2023, after the market closes. A conference call featuring CEO Katherine Stueland and CFO Kevin Feeley will follow at 4:30 PM ET to discuss the company's financial and operational performance. GeneDx specializes in genomic and clinical insights, aiming to enhance health outcomes via precision medicine. The company is well-positioned in the healthcare sector, leveraging extensive rare disease data for its genomic testing and interpretation services.
- Anticipated financial results may show growth in genomic testing services.
- Company's focus on precision medicine aligns with industry trends towards personalized healthcare.
- No current financial metrics available which could impact investor sentiment.
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter and full year of 2022 after the market closes on Tuesday, March 14, 2023. On the same day, Katherine Stueland, Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.
Conference Call Details
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.
About GeneDx
GeneDx, (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
Investor Relations Contact:
Tricia Truehart
investors@GeneDx.com
Media Contact:
Stephanie Kahan
press@GeneDx.com
FAQ
When will GeneDx release its Q4 2022 financial results?
What time is the GeneDx conference call scheduled for?
What is the focus of GeneDx's business?
How can investors access the GeneDx conference call?
